Every one of those 1 sits in a single category, earnings. Acclarent is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 6 in the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Integra LifeSciences
Every one of those 1 sits in a single category, earnings. Acclarent is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 6 in the same window. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. We currently track 1 Finance story that mention Integra LifeSciences, all published on February 26, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 120 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Integra LifeSciences. Shared-story counts are live from our verified record — not editorial picks.
Integra LifeSciences (IART) shares faced downward pressure following its Q4 2025 earnings call, as management detailed an extended timeline for its Boston facility restart and the ongoing costs of its Quality Excellence Program. While the company provided its first full-year 2026 guidance, investor caution remains high regarding the path to normalized growth and product re-launches.
Integra LifeSciences is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.